Skip to content
Screener

Prime Medicine PRME Q4 2025 Annual earnings

Reported March 3, 2026 · Before market open

Revenue$842.0KMiss by $445.4K
EPS-$0.22Beat by $0.03
Revenue estimate$1.3M
EPS estimate-$0.25

Next report

Nov 6, 2026 (in 2 months)
Revenue estimate$1.3M
EPS estimate-$0.23

Financials

Q4 2025

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$48.6M-9.9%
Net income-$46.1M-9.0%
EPS (diluted)-$0.24+22.6%

Balance sheet

See full
Cash & equivalents$76.7M-61.0%
Total debt$116.4M+185%
Total equity$120.9M-21.1%
Total assets$342.7M+15.2%

Cash flow

See full
Operating cash flow-$37.3M—
CapEx$290.0K-83.8%
Free cash flow-$37.5M—

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$626.37M+63.5%
Enterprise value$666.08M+193%
P/S135.2×+6.8×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%—

Returns & leverage

See full
Return on equity-146.8%+11.5pp
Debt / equity1×+0.7×
Current ratio4.8×-0.7×

Segments

By segment

See full
Reportable Segment$838.0K-61.6%

FAQ

When did Prime Medicine report Q4 2025 earnings?
Prime Medicine (PRME) reported Q4 2025 earnings on March 3, 2026 before market open.
What were Prime Medicine's Q4 2025 revenue and EPS?
Prime Medicine reported revenue of $842.0K and eps of $-0.22 for Q4 2025.
Did Prime Medicine beat estimates in Q4 2025?
Revenue missed the consensus estimate of $1.3M by $445.4K. EPS beat the consensus estimate of $-0.25 by $0.03.
How did Prime Medicine's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 61.4% from $2.2M a year earlier and eps grew 29.0% from $-0.31.
Where can I find Prime Medicine's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001628280-26-013565) and the 10-K periodic report (0001628280-26-013569) directly on SEC EDGAR. The filing index links above go to sec.gov.